Encompass Health Maintains 2025 Guidance: Adjusted EBITDA $1.185-$1.220 Billion, Adjusted EPS $4.85-$5.10

Reuters
04 Jun
Encompass Health Maintains 2025 Guidance: Adjusted EBITDA $1.185-$1.220 Billion, Adjusted EPS $4.85-$5.10

Encompass Health Corporation has reiterated its financial outlook for the full year 2025. The company forecasts net operating revenue between $5,850 million and $5,925 million. Adjusted EBITDA is expected to range from $1,185 million to $1,220 million. Additionally, the company projects adjusted earnings per share from continuing operations attributable to Encompass Health to be between $4.85 and $5.10. The company has refrained from providing guidance on a GAAP basis, except for net operating revenues, due to the unpredictability of certain external factors that could impact its financial results. These include various settlements, professional fees, and other items not indicative of ongoing performance. However, for 2025, Encompass Health estimates interest expense and amortization of debt discounts and fees to be approximately $125 million, and amortization of debt-related items to be around $10 million. Members of the company's senior management team are scheduled to meet with investors and analysts in June 2025 to discuss these projections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Encompass Health Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000785161-25-000028), on June 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10